AU2019282132A1 - Compositions and methods for treating pancreatitis - Google Patents

Compositions and methods for treating pancreatitis Download PDF

Info

Publication number
AU2019282132A1
AU2019282132A1 AU2019282132A AU2019282132A AU2019282132A1 AU 2019282132 A1 AU2019282132 A1 AU 2019282132A1 AU 2019282132 A AU2019282132 A AU 2019282132A AU 2019282132 A AU2019282132 A AU 2019282132A AU 2019282132 A1 AU2019282132 A1 AU 2019282132A1
Authority
AU
Australia
Prior art keywords
pcsk9
pcsk9 inhibitor
use according
pancreatitis
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019282132A
Other languages
English (en)
Other versions
AU2019282132A8 (en
Inventor
Brian K. Hubbard
Charles D. Meyers
Michael H. Serrano-Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anji Pharmaceuticals Inc
Original Assignee
Anji Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anji Pharmaceuticals Inc filed Critical Anji Pharmaceuticals Inc
Publication of AU2019282132A1 publication Critical patent/AU2019282132A1/en
Publication of AU2019282132A8 publication Critical patent/AU2019282132A8/en
Assigned to ANJI PHARMACEUTICALS INC. reassignment ANJI PHARMACEUTICALS INC. Request for Assignment Assignors: ANJI PHARMA (US) LLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C12Y304/11001—Leucyl aminopeptidase (3.4.11.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2019282132A 2018-06-05 2019-06-04 Compositions and methods for treating pancreatitis Abandoned AU2019282132A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680896P 2018-06-05 2018-06-05
US62/680,896 2018-06-05
PCT/US2019/035310 WO2019236528A1 (en) 2018-06-05 2019-06-04 Compositions and methods for treating pancreatitis

Publications (2)

Publication Number Publication Date
AU2019282132A1 true AU2019282132A1 (en) 2020-12-17
AU2019282132A8 AU2019282132A8 (en) 2023-05-25

Family

ID=68770590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019282132A Abandoned AU2019282132A1 (en) 2018-06-05 2019-06-04 Compositions and methods for treating pancreatitis

Country Status (9)

Country Link
US (1) US11679146B2 (https=)
EP (1) EP3801620A4 (https=)
JP (1) JP2021532167A (https=)
CN (1) CN112512574A (https=)
AU (1) AU2019282132A1 (https=)
CA (1) CA3102032A1 (https=)
MX (1) MX2020013155A (https=)
TW (1) TW202015727A (https=)
WO (1) WO2019236528A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
WO2022002160A1 (zh) * 2020-07-01 2022-01-06 陈敏 Pcsk9抑制剂在制备治疗多种疾病产品中的应用
CN114250194B (zh) * 2021-11-30 2023-04-11 四川大学华西医院 一种急性胰腺炎细胞模型的构建方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856487A (en) 1996-02-14 1999-01-05 National Institute Of Immunology Application of protoberberine alkaloid, berberine, an immunosuppressive agent
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CN101467999A (zh) 2007-12-25 2009-07-01 郑州后羿制药有限公司 一种盐酸小檗碱复方制剂
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
CN101829113B (zh) 2009-07-14 2012-12-12 武汉大学 黄连素在治疗或预防流感病毒药物中的应用
AU2010298249A1 (en) 2009-09-23 2012-04-19 Carolus Therapeutics, Inc. Methods of treating inflammation
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
EP2849788B1 (en) * 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
CN104815316A (zh) 2015-05-25 2015-08-05 苗怡文 一种治疗急慢性胰腺炎的中药制剂及其制备方法
US20190365656A1 (en) 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
CN107468687A (zh) 2017-09-05 2017-12-15 吴蕾 黄连素作为细胞m3受体抑制剂的用途
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis

Also Published As

Publication number Publication date
US11679146B2 (en) 2023-06-20
MX2020013155A (es) 2021-04-29
US20210213111A1 (en) 2021-07-15
EP3801620A1 (en) 2021-04-14
CA3102032A1 (en) 2019-12-12
JP2021532167A (ja) 2021-11-25
AU2019282132A8 (en) 2023-05-25
CN112512574A (zh) 2021-03-16
WO2019236528A1 (en) 2019-12-12
EP3801620A4 (en) 2022-04-20
TW202015727A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
US11679146B2 (en) Compositions and methods for treating pancreatitis
Zhang et al. Knockdown of lncRNA PVT1 inhibits vascular smooth muscle cell apoptosis and extracellular matrix disruption in a murine abdominal aortic aneurysm model
Glerup et al. Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Abbad et al. Advances and challenges in kidney fibrosis therapeutics
Seidah et al. PCSK9: a key modulator of cardiovascular health
EP4663250A2 (en) Methods for treating nasal polyposis by administering an il-4r antagonist
KR20170136542A (ko) C/EBP 알파 saRNA 조성물 및 사용 방법
EP3515465B1 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
EP4011915A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2013170367A1 (en) Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
Tamargo et al. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
Unzu et al. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice
Chen et al. A review of PCSK9 inhibitors and their effects on cardiovascular diseases
AU2020367770A1 (en) Compositions and methods for treating liver disease
Chang et al. Macrophage inflammatory protein-1β as a novel therapeutic target for renal protection in diabetic kidney disease
Shi et al. Calcitriol attenuates liver fibrosis through hepatitis C virus nonstructural protein 3-transactivated protein 1-mediated TGF β1/Smad3 and NF-κB signaling pathways
Shi et al. Ganglioside GA2-mediated caspase-11 activation drives macrophage pyroptosis aggravating intimal hyperplasia after arterial injury
Buras et al. Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice
CN120505318B (zh) LSR、LncRNA-LSR-AS1或靶向siRNA在预防和/或治疗高脂血症或其相关疾病中的应用
He et al. Pretreatment with interleukin-15 attenuates inflammation and apoptosis by inhibiting NF-κB signaling in sepsis-induced myocardial dysfunction
EP4634382A1 (en) Rnai-based therapies targeting claudin-1 for the treatment and prevention of fibrotic diseases
Xie et al. Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy
JP2024063069A (ja) 喘息及びアレルギー性疾患を処置するための方法及び組成物
US20130236480A1 (en) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
Dass PEDF and its role in metabolic disease, angiogenesis, cardiovascular disease, and diabetes

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 50 , PAGE(S) 7218 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ANJI PHARMA, APPLICATION NO. 2019282132, UNDER INID (71) CORRECT THE APPLICANT NAME TO ANJI PHARMA (US) LLC

PC1 Assignment before grant (sect. 113)

Owner name: ANJI PHARMACEUTICALS INC.

Free format text: FORMER APPLICANT(S): ANJI PHARMA (US) LLC

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application